RxDoctor Payments Data

Dorothy Tata-Oyekan, MD

Family Medicine · Louisville, KYNPI 1760739841

Payments from drug & device makers

$3,070in general payments, 2019–2025

Across 86 payments — averaging $35.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$678
  • AstraZeneca$576
  • Phathom Pharmaceuticals, Inc.$335
  • Pfizer$224
  • Exact Sciences$207
  • Biohaven Pharmaceutical Holding Company Ltd.$180
  • plus $870 from 23 others

What the payments were for

  • Food & beverage$3,056100%
  • Education$140%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,070 in reported general payments places this provider in the 75th percentile of 1,559 family medicine providers in Kentucky.

See all family medicine providers in Kentucky

Medicare billing

Part B allowed, 2024
$67,443
Medicare patients
149
Services billed
873

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide66$85,992
JardianceEmpagliflozin39$51,176
EliquisApixaban26$33,295
FarxigaDapagliflozin Propanediol20$29,115
TrulicityDulaglutide16$21,597
MounjaroTirzepatide15$17,778
Breo ElliptaFluticasone/Vilanterol25$15,822
Tresiba Flextouch U-100Insulin Degludec25$13,483
Albuterol Sulfate HfaAlbuterol Sulfate61$3,021
Atorvastatin Calcium288$2,109
SynthroidLevothyroxine Sodium19$1,656
Levothyroxine Sodium198$1,571
Metoprolol Succinate90$1,292
Duloxetine Hcl33$1,077
Gabapentin81$1,070

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$678$85,99266 claims
Boehringer IngelheimJardiance$26$51,17639 claims
Lilly USA, LLCTrulicity, Mounjaro$51$39,37531 claims
PfizerEliquis$224$33,29526 claims
AstraZenecaFarxiga$576$29,11520 claims
GSKBreo Ellipta$36$15,82225 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,559 family medicine providers in Kentucky.

Other family medicine in Louisville

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →